Development of therapies against neuromuscular diseases causing muscle atrophy

Research output: Contribution to journalShort survey

1 Citation (Scopus)

Abstract

Skeletal muscles become atrophied by muscular disorders such as muscular dystrophy, wasting and even aging. In addition to muscle atrophy, progressive muscle damage, inflammation and replacement of muscle fibers with fibrous and fatty tissues are observed in muscular dystrophy. Neuronal innervation is required for skeletal muscle, and muscles become atrophic when motor neurons are affected by neurodegenerative disorders such as amyotrophic lateral sclerosis. Restoring muscle mass and function lost by diseases such as muscular dystrophy and neurodegenerative disorders is important. There are three rational therapies for muscular dystrophy and related diseases: gene therapy, cell therapy and drug therapy. Gene therapies to replace the defective genes have been tried with various degrees of effectiveness. Multiple myogenic stem cells including satellite cells, bone marrow cells, muscle side population cells, muscle-derived stem cells and mesoangioblast have been characterized. Cell therapies using these stem cells are one of the promising therapies for neuromuscular diseases causing muscle atrophy. As pharmacological drug therapies, increasing skeletal muscle mass by myostatin inhibition is quite promising and will be applied clinically in the near future.

Original languageEnglish
Pages (from-to)229-233
Number of pages5
JournalJapanese Journal of Neuropsychopharmacology
Volume26
Issue number5-6
Publication statusPublished - 01-11-2006

Fingerprint

Neuromuscular Diseases
Muscular Atrophy
Muscular Dystrophies
Muscles
Skeletal Muscle
Stem Cells
Cell- and Tissue-Based Therapy
Neurodegenerative Diseases
Genetic Therapy
Side-Population Cells
Myostatin
Therapeutics
Drug Therapy
Amyotrophic Lateral Sclerosis
Motor Neurons
Bone Marrow Cells
Muscle Cells
Adipose Tissue
Pharmacology
Inflammation

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{4c9384c5ab1a4851ac1cd9e4c0c15756,
title = "Development of therapies against neuromuscular diseases causing muscle atrophy",
abstract = "Skeletal muscles become atrophied by muscular disorders such as muscular dystrophy, wasting and even aging. In addition to muscle atrophy, progressive muscle damage, inflammation and replacement of muscle fibers with fibrous and fatty tissues are observed in muscular dystrophy. Neuronal innervation is required for skeletal muscle, and muscles become atrophic when motor neurons are affected by neurodegenerative disorders such as amyotrophic lateral sclerosis. Restoring muscle mass and function lost by diseases such as muscular dystrophy and neurodegenerative disorders is important. There are three rational therapies for muscular dystrophy and related diseases: gene therapy, cell therapy and drug therapy. Gene therapies to replace the defective genes have been tried with various degrees of effectiveness. Multiple myogenic stem cells including satellite cells, bone marrow cells, muscle side population cells, muscle-derived stem cells and mesoangioblast have been characterized. Cell therapies using these stem cells are one of the promising therapies for neuromuscular diseases causing muscle atrophy. As pharmacological drug therapies, increasing skeletal muscle mass by myostatin inhibition is quite promising and will be applied clinically in the near future.",
author = "Kunihiro Tsuchida",
year = "2006",
month = "11",
day = "1",
language = "English",
volume = "26",
pages = "229--233",
journal = "Japanese Journal of Psychopharmacology",
issn = "1343-4144",
publisher = "Japanese Society of Neuropsychopharmacology",
number = "5-6",

}

Development of therapies against neuromuscular diseases causing muscle atrophy. / Tsuchida, Kunihiro.

In: Japanese Journal of Neuropsychopharmacology, Vol. 26, No. 5-6, 01.11.2006, p. 229-233.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Development of therapies against neuromuscular diseases causing muscle atrophy

AU - Tsuchida, Kunihiro

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Skeletal muscles become atrophied by muscular disorders such as muscular dystrophy, wasting and even aging. In addition to muscle atrophy, progressive muscle damage, inflammation and replacement of muscle fibers with fibrous and fatty tissues are observed in muscular dystrophy. Neuronal innervation is required for skeletal muscle, and muscles become atrophic when motor neurons are affected by neurodegenerative disorders such as amyotrophic lateral sclerosis. Restoring muscle mass and function lost by diseases such as muscular dystrophy and neurodegenerative disorders is important. There are three rational therapies for muscular dystrophy and related diseases: gene therapy, cell therapy and drug therapy. Gene therapies to replace the defective genes have been tried with various degrees of effectiveness. Multiple myogenic stem cells including satellite cells, bone marrow cells, muscle side population cells, muscle-derived stem cells and mesoangioblast have been characterized. Cell therapies using these stem cells are one of the promising therapies for neuromuscular diseases causing muscle atrophy. As pharmacological drug therapies, increasing skeletal muscle mass by myostatin inhibition is quite promising and will be applied clinically in the near future.

AB - Skeletal muscles become atrophied by muscular disorders such as muscular dystrophy, wasting and even aging. In addition to muscle atrophy, progressive muscle damage, inflammation and replacement of muscle fibers with fibrous and fatty tissues are observed in muscular dystrophy. Neuronal innervation is required for skeletal muscle, and muscles become atrophic when motor neurons are affected by neurodegenerative disorders such as amyotrophic lateral sclerosis. Restoring muscle mass and function lost by diseases such as muscular dystrophy and neurodegenerative disorders is important. There are three rational therapies for muscular dystrophy and related diseases: gene therapy, cell therapy and drug therapy. Gene therapies to replace the defective genes have been tried with various degrees of effectiveness. Multiple myogenic stem cells including satellite cells, bone marrow cells, muscle side population cells, muscle-derived stem cells and mesoangioblast have been characterized. Cell therapies using these stem cells are one of the promising therapies for neuromuscular diseases causing muscle atrophy. As pharmacological drug therapies, increasing skeletal muscle mass by myostatin inhibition is quite promising and will be applied clinically in the near future.

UR - http://www.scopus.com/inward/record.url?scp=33846117573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846117573&partnerID=8YFLogxK

M3 - Short survey

C2 - 17240849

AN - SCOPUS:33846117573

VL - 26

SP - 229

EP - 233

JO - Japanese Journal of Psychopharmacology

JF - Japanese Journal of Psychopharmacology

SN - 1343-4144

IS - 5-6

ER -